Brief: Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration Of Bel-Sar In Patients With Non-Muscle-Invasive Bladder Cancer (NMIBC) In Ongoing Phase 1 Trial
17/10/2024 21:09
Oct 17 (Reuters) - Aura Biosciences Inc AURA.O :
* MULTIPLE CLINICAL COMPLETE RESPONSES DEMONSTRATED
FOLLOWING
SINGLE LOW DOSE ADMINISTRATION OF BEL-SAR IN PATIENTS WITH
NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) IN ONGOING PHASE 1
TRIAL
* AURA BIOSCIENCES INC - FAVORABLE SAFETY PROFILE WITH LESS
THAN
10% GRADE 1 ADVERSE EVENTS
Source text for Eikon: ID:nGNX4mb28Q
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs